Teva Pharmaceutical Industries Ltd (TEVA)

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple SclerosisJuly 9, 2026 8:45 AM
Business Wire Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations. Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and development capabilities creates a clear path to getting this medicine to patients who need more treatment options.” Under the terms of the agreement, Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar candidate. Teva will be responsible for regulatory submissions and, upon approval, commercialization of the intravenous and subcutaneous formulations in the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel and Turkey. “This agreement is aligned with Teva’s Pivot to Growth strategy and our focus on expanding our biosimilars pipeline. With our global commercial footprint and deep expertise in complex medicines, we are well positioned to help bring this biosimilar candidate to patients,” said Yolanda Tibbe, Vice President, Global Head of Biosimilars at Teva. This strategic agreement reinforces both organizations’ commitment to broadening access to biologic medicines while promoting the long-term sustainability of healthcare systems. About ocrelizumab Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, which are believed to play a role in the autoimmune activity associated with multiple sclerosis. Ocrevus® (ocrelizumab) is indicated for the treatment of relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. In the U.S., the intravenous formulation is marketed as Ocrevus®, while the subcutaneous formulation is marketed separately as Ocrevus Zunovo® (ocrelizumab and hyaluronidase-ocsq). In the EU, both formulations carry the single brand name Ocrevus®. About Multiple Sclerosis Multiple sclerosis is a chronic, unpredictable and progressive disease of the central nervous system, which includes the brain and spinal cord. In MS, the loss of myelin, the protective sheath surrounding nerve fibers, disrupts the transmission of electrical signals to and from the brain, leading to a wide range of symptoms. MS affects people differently. Symptoms can fluctuate, with periods of worsening (relapses) followed by partial or full recovery (remission). Over time, some patients may also experience a gradual progression of disability. Common symptoms include fatigue, weakness, numbness or tingling, walking difficulties, spasticity, dizziness, and vision problems, among others. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com. About Polpharma Biologics Polpharma Biologics International AG is a biopharmaceutical company focused on development and manufacturing of biosimilars for supply to global markets. We manage the entire value chain: from product selection and investment allocation, through program execution to asset monetization, ensuring fast progress from idea to launch in strong collaboration with our global partners. Our international team of senior experts has proven experience in program leadership, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. Working with trusted CDMOs and CROs, we deliver end-to-end biosimilars, from cell line to finished product, across a range of major therapeutic areas. Our commercial partners ensure access for patients to these medicines worldwide. Our mission is to accelerate access to biologics. To fulfill that mission, we maintain a robust, expanding pipeline of biosimilars in development. www.polpharmabiologics.com Teva Cautionary Note Regarding Forward-Looking Statements This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute our collaboration agreement with Polpharma Biologics for the commercialization of its biosimilar candidate to ocrelizumab, upon regulatory approval; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward-looking statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. 1 Ocrevus® and Ocrevus Zunovo® are registered trademarks of Genentech, Inc. and/or F. Hoffmann-La Roche Ltd.   View source version on businesswire.com: https://www.businesswire.com/news/home/20260709701277/en/ Media Contact – Polpharma Biologics
Stephanie Deitzer
Lead Transformation & Communications
Polpharma Biologics International AG
stephanie.deitzer@polpharmabiologics.ch
+41 78 600 53 59 Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com Teva Investor Relations Inquiries
TevaIR@Tevapharm.com Original: Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Teva et Samsung Bioepis annoncent la conclusion d'une entente de commercialisation pour OPUVIZ(MD), un biosimilaire d'Eylea® (aflibercept), au CanadaJuly 9, 2026 8:05 AM
PR Newswire (Canada) TORONTO, Canada et INCHEON, South Korea, le 9 juill. 2026 /CNW/ - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) et Samsung Bioepis Co., Ltd., ont annoncé aujourd'hui que les deux entreprises ont conclu une entente de licence et de commercialisation pour OPUVIZMD (aflibercept), un biosimilaire d'Eylea1 (aflibercept), au Canada. En vertu de cette entente, Samsung Bioepis est responsable de l'homologation et de la fabrication des produits, tandis que Teva Canada (une filiale de Teva Pharmaceutical Industries Ltd.) est responsable de leur commercialisation.« Cette entente est une étape importante de l'enrichissement de notre portefeuille de biosimilaires au Canada, a déclaré Fabien Paquette, directeur général de Teva Canada. Elle nous permet de continuer sur notre lancée en ce qui concerne les biosimilaires et d'accentuer notre présence dans le domaine de l'ophtalmologie, et elle reflète notre engagement d'offrir des options thérapeutiques de grande qualité aux patients et aux professionnels de la santé canadiens grâce à des partenariats stratégiques. »« Cette entente représente une étape importante de l'avancement de notre stratégie de croissance en Amérique du Nord et de l'élargissement de l'accès aux médicaments biologiques ophtalmiques au Canada, a affirmé Kwang Ryu, vice-président et responsable de l'équipe chargée du développement des affaires à Samsung Bioepis. Par l'entremise de notre collaboration avec Teva, nous nous engageons à élargir l'accès à des options thérapeutiques de grande qualité au Canada et à aider ainsi davantage de patients à bénéficier de soins durables en temps opportun. »OPUVIZ a obtenu l'approbation de Santé Canada en octobre 2025 et est indiqué dans le traitement de la forme néovasculaire (humide) de la dégénérescence maculaire liée à l'âge (DMLA), de la déficience visuelle due à un œdème maculaire secondaire à une occlusion de la veine centrale de la rétine (OVCR) ou à une occlusion de la branche veineuse rétinienne (OBVR), de l'œdème maculaire diabétique (OMD) et de la néovascularisation choroïdienne (NVC) myopique.L'aflibercept biosimilaire de Samsung Bioepis est également disponible en Europe et dans la République de Corée.Teva Canada communiquera d'autres détails sur le lancement prévu d'OPUVIZMD sur le marché canadien au moment opportun.Veuillez consulter la monographie de produit d'OPUVIZ (aflibercept), y compris les renseignements importants sur l'innocuité ICI.AVIS DE NON-RESPONSABILITÉ
Le présent communiqué de presse vise uniquement à annoncer la disponibilité d'OPUVIZ au Canada. Ce document ne doit pas être interprété comme un avis médical ou comme la recommandation d'un produit ou d'un traitement. L'état de l'homologation réglementaire et les renseignements thérapeutiques peuvent varier d'un pays à l'autre; veuillez donc vous reporter à la version locale des renseignements sur le produit pour les médicaments mentionnés dans le présent document. Les informations qui figurent dans le présent communiqué de presse peuvent inclure des données portant sur des composés expérimentaux ou sur des indications non approuvées. Ces informations sont communiquées aux fins de discussion scientifique seulement et ne représentent en aucun cas une assertion sur l'innocuité ou l'efficacité d'une utilisation non approuvée. Le présent communiqué de presse peut contenir des énoncés prospectifs, y compris des énoncés concernant des programmes de développement clinique, des soumissions réglementaires, des homologations potentielles et le potentiel thérapeutique futur. Ces énoncés sont basés sur les attentes et les hypothèses actuelles et sont assujettis à des risques et incertitudes qui pourraient faire dévier les résultats réels d'une manière significative. Les énoncés prospectifs ne constituent pas des garanties quant au rendement futur. Samsung Bioepis n'est pas tenue de mettre à jour les énoncés prospectifs contenus dans le présent communiqué de presse.À propos de Teva
Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA) est en voie de se transformer en une entreprise biopharmaceutique novatrice de premier plan grâce à ses produits génériques de classe internationale. Depuis plus de 120 ans, l'engagement de Teva envers l'amélioration de la santé n'a jamais flanché. Qu'il s'agisse d'innover dans le domaine des neurosciences et de l'immunologie ou de produire des médicaments génériques complexes, des biosimilaires et des marques parapharmaceutiques à l'échelle planétaire, Teva s'est donné pour mission de répondre aux besoins des patients, aujourd'hui et demain. Au sein de Teva, nous avons tous à cœur d'améliorer la santé. Pour en apprendre davantage à ce propos, visitez le www.tevapharm.com.À propos de Samsung Bioepis Co., Ltd.
Fondée en 2012, Samsung Bioepis est une entreprise biopharmaceutique déterminée à fabriquer des médicaments qui sont accessibles à tous. Grâce à des innovations dans le développement des nouveaux produits et à son ferme engagement envers la qualité, Samsung Bioepis vise à devenir la principale entreprise biopharmaceutique au monde. En tant que filiale en propriété exclusive de Samsung Epis Holdings, Samsung Bioepis continue de faire progresser son vaste portefeuille de candidats biologiques en voie de commercialisation qui couvrent un éventail de classes thérapeutiques, y compris dans le domaine de l'immunologie, de l'oncologie, de l'ophtalmologie, de l'hématologie, de la néphrologie, de l'endocrinologie et de la neurologie. Pour en savoir plus, consultez le www.samsungbioepis.com et suivez-nous sur LinkedIn et sur X.Mise en garde de Teva concernant les énoncés prospectifs
Le présent communiqué de presse contient des énoncés prospectifs au sens de la Private Securities Litigation Reform Act of 1995 des États-Unis, énoncés qui sont basés sur les convictions et les attentes actuelles de la direction et qui sont assujettis à des risques et incertitudes considérables, connus et inconnus, qui pourraient faire dévier d'une manière significative nos résultats, nos réalisations ou notre rendement futurs de ceux qui sont exprimés ou suggérés par ces énoncés prospectifs. Les énoncés prospectifs sont reconnaissables à l'emploi de verbes comme « devoir », « prévoir », « penser », « estimer », « cibler », « pouvoir », « prévoir », « avoir l'intention de », « planifier » et « croire » ou d'autres termes et expressions similaires à propos de discussions portant sur les résultats d'exploitation ou sur le rendement financier futurs. Parmi les facteurs importants qui pourraient causer ces écarts ou y contribuer, on observe les risques ayant un lien avec : notre capacité d'exécuter avec succès l'entente de licence, de développement et de commercialisation que nous avons conclue avec Samsung Bioepis Co., Ltd. pour OPUVIZ (aflibercept), un biosimilaire d'Eylea®; notre capacité de commercialiser avec succès OPUVIZ (aflibercept) au Canada; notre capacité de supplanter avec succès nos concurrents sur le marché, y compris notre capacité de développer et de commercialiser d'autres produits pharmaceutiques; notre capacité de réaliser avec succès notre stratégie « Tournés vers la croissance », y compris l'accroissement de notre portefeuille de médicaments innovants et biosimilaires et la commercialisation rentable de ce portefeuille, que ce soit par nos propres moyens ou par l'entremise du développement de nos affaires et par l'accomplissement de notre transformation organisationnelle et la réalisation des économies attendues; enfin, d'autres facteurs discutés dans le présent communiqué de presse, dans notre rapport trimestriel sur le formulaire 10-Q pour le premier trimestre de 2026 et dans notre rapport annuel sur le formulaire 10-K pour l'exercice clos le 31 décembre 2025, y compris dans les sections intitulées « Facteurs de risque » et « Énoncés prospectifs ». Les énoncés prospectifs ne valent que pour la date à laquelle ils ont été émis, et nous ne sommes pas tenus de mettre à jour ou de réviser les énoncés prospectifs ou les autres informations qu'ils contiennent, que ce soit à la lumière de nouvelles informations ou d'évènements futurs ou autrement. Par conséquent, nous vous conseillons de ne pas vous fier indûment à ces énoncés prospectifs._____________________________1Eylea est une marque de commerce déposée de Regeneron Pharmaceuticals, Inc. SOURCE Teva Canada Original: Teva et Samsung Bioepis annoncent la conclusion d'une entente de commercialisation pour OPUVIZ(MD), un biosimilaire d'Eylea® (aflibercept), au Canada

Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea® (aflibercept), in CanadaJuly 9, 2026 8:05 AM
PR Newswire (Canada) TORONTO, Canada and INCHEON, South Korea, July 9, 2026 /CNW/ - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that the companies have entered into a license and commercialization agreement for OPUVIZ® (aflibercept), a biosimilar referencing Eylea®1 (aflibercept), in Canada. Under the agreement, Samsung Bioepis is responsible for registration and manufacture of the products, while Teva Canada (a subsidiary of Teva Pharmaceutical Industries Ltd.) is responsible for commercialization."This agreement is an important step in strengthening our biosimilars portfolio in Canada," said Fabien Paquette, General Manager, Teva Canada. "It continues to build on our momentum in biosimilars, to expand our ophthalmology footprint, and reflects our commitment to bringing high-quality treatment options to Canadian patients and healthcare professionals through strategic partnerships.""This agreement represents an important step in advancing our growth strategy in North America and expanding access of ophthalmic biologic medicines in Canada," said Kwang Ryu, Vice President and Team Leader of Business Development at Samsung Bioepis. "Through our collaboration with Teva we are committed to expanding access to high-quality treatment options in Canada and helping more patients benefit from timely and sustainable care."OPUVIZ received Health Canada approval in October 2025 and is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment resulting from macular edema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV).Samsung Bioepis' aflibercept biosimilar is also available in Europe and in Republic of Korea.Teva Canada will provide further details on the anticipated Canadian market launch of OPUVIZ® at the appropriate time.Please see Product Monograph for OPUVIZ (aflibercept) including important safety information HERE. DISCLAIMER
This press release is intended solely for the purpose of sharing the availability of OPUVIZ in Canada. This document should not be construed as medical advice or as an endorsement of any product or treatment. Regulatory approval status and prescribing information may vary by country; please refer to local product information for any medicinal products mentioned herein. Information in this press release may include data on investigational compounds or unapproved indications. Such information is shared for scientific discussion purposes only and does not represent an assertion of safety or efficacy for any unapproved use. This press release may contain forward-looking statements, including statements regarding clinical development programs, regulatory submissions, potential approvals, and future therapeutic potential. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are not guarantees of future performance. Samsung Bioepis undertakes no obligation to update any forward-looking statements contained in this press release.About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars, and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology and neurology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X. Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute our license, development and commercialization agreement with Samsung Bioepis Co., Ltd. for OPUVIZ (aflibercept), a biosimilar referencing Eylea®; our ability to successfully commercialize OPUVIZ (aflibercept) in Canada; our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.1Eylea® is a trademark of Regeneron Pharmaceuticals, Inc. SOURCE Teva Canada Original: Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea® (aflibercept), in Canada

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

Mon, May 18, 2026 at 3:30 PM GMT+3 4 min read


TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB+.

“This strong endorsement, our third upgrade from Fitch in less than two years, underscores Teva’s transformation journey and execution of its Pivot to Growth strategy, as well as shows confidence in our increasing financial flexibility” said Eli Kalif, Teva’s Chief Financial Officer.

Fitch has also upgraded its ratings on Teva's senior unsecured debt and credit facilities to BBB- from BB+.

Fitch’s report highlights Teva’s sustained progress in strengthening financial flexibility and advancing its transition toward a higher-margin innovative and biosimilar portfolio. Fitch expects continued growth in innovative revenues, led by AUSTEDO® and AJOVY®; as well as contributions from recently launched products such as UZEDY® and upcoming launches, including olanzapine LAI, subject to regulatory approval. Fitch also expects Teva’s efficiency programs and portfolio shift to support its operating margin improvement and continued strong cash generation. Fitch further noted Teva’s ongoing balance sheet strengthening, supported by sustained cash flow generation, enhancing financial flexibility.

Teva is currently rated BB+ with stable outlook by S&P Global Ratings and Ba1 with positive outlook by Moody’s Investors Service.

Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Thu, April 30, 2026

https://finance.yahoo.com/sectors/healthcare/articles/teva-2025-healthy-future-report-123000206.html

Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced environmental impact.

Through its global access to medicines programs, Teva reached nearly 8 million people through product donations around the world.

39% reduction in Teva’s Scope 1 and 2 GHG emissions since 2019 and 32% reduction in Scope 3 GHG emissions since 2020—exceeding 25% reduction targets.

More than 99% of active employees completed compliance and ethics training.

Teva’s generic medicines contributed $36.4 billion in savings for healthcare systems across 21 countries.

Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy

https://finance.yahoo.com/sectors/healthcare/articles/teva-signs-off-900m-emalex-110100359.html

Annabel Kartal Allen

Teva Pharmaceuticals will acquire neuroscience specialist, Emalex – a move which Teva executive, Evan Lippman, says effectively complements the company’s wider “pivot to growth” strategy.

Through this agreement, which will set Teva back $700m upfront and up to $200m in potential milestones, the biopharma company will absorb Emalex’s neurology-focused pipeline. This includes ecopipam, Emalex’s first-in-class therapy for paediatric Tourette’s syndrome, which has already secured a Phase III win.

PONLIMSI Biosimilar Approval and Xolair Filings Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA)

https://finance.yahoo.com/sectors/healthcare/articles/ponlimsi-biosimilar-approval-xolair-filings-211210937.html

Thu, April 2, 2026 at 12:12 AM GMT

Teva Pharmaceutical Industries recently reported FDA approval of PONLIMSI (denosumab-adet) as a Prolia biosimilar for all reference indications, alongside FDA and EMA acceptance of its proposed Xolair (omalizumab) biosimilar filings.

These moves deepen Teva’s presence in higher-value biosimilars, reinforcing its Pivot to Growth plan and shifting more of its portfolio toward complex biopharmaceutical products.

We’ll now examine how the FDA approval of PONLIMSI, in particular, may reshape Teva’s investment narrative and future earnings mix.

Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Teva Pharmaceutical Industries Investment Narrative Recap
To own Teva today, you need to believe its Pivot to Growth can gradually shift the story from low-growth generics toward higher-margin branded and biosimilar drugs, while its heavy US$15 billion-plus net debt burden keeps trending down. The PONLIMSI approval supports the near term growth narrative around complex biosimilars, but it does not remove the key risks of execution across the broader pipeline or potential pricing and volume pressure in generics.

Among recent developments, the FDA and EMA acceptance of Teva’s Xolair biosimilar filings sits closest to the PONLIMSI news, together underscoring the company’s push into higher-value biosimilars. If regulators ultimately approve the Xolair candidate as well, investors will likely focus even more on how quickly these newer products can change Teva’s earnings mix relative to its more mature generics base.


Yet, against this progress, investors should also weigh how sustained price pressure in generics and biosimilars could still challenge Teva’s margin ambitions...

Medincell : La FDA américaine accepte le dossier de demande de mise sur le marché déposé par Teva pour l’Olanzapine LAIFebruary 20, 2026 3:37 PM
Business Wire
Olanzapine LAI (TEV-’749 / mdc-TJK) est une suspension injectable d’olanzapine à libération prolongée pour le traitement de la schizophrénie chez l’adulte, administrée une fois par mois


L’Olanzapine LAI pourrait offrir l’efficacité de l’olanzapine en injection sous-cutanée administrée mensuellement1.


Si elle est approuvée après l’examen du dossier par la FDA2, l’Olanzapine LAI pourrait contribuer à répondre à un besoin médical important encore non satisfait dans le traitement de la schizophrénie, en comblant l’absence de formulations viables d’olanzapine à action prolongée1.


Teva poursuit le développement de cette option thérapeutique innovante et le renforcement de son portefeuille différencié de traitements injectables à action prolongée (LAI), consolidant ainsi son leadership scientifique dans les pathologies neurologiques complexes, dans le cadre de sa stratégie Pivot to Growth.


Regulatory News:


Teva Pharmaceuticals, filiale américaine de Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA), et Medincell (Euronext : MEDCL), annoncent que la Food and Drug Administration (FDA) américaine a accepté le dossier de demande d'autorisation de mise sur le marché américain (NDA) de l’injection sous-cutanée à libération prolongée d’olanzapine (TEV-‘749) pour le traitement de la schizophrénie chez l’adulte. L’Olanzapine LAI est conçue pour favoriser l’observance dans la vie réelle et améliorer la stabilité clinique, avec un objectif de répondre à un besoin thérapeutique majeur pour les personnes atteintes de schizophrénie.


À ce jour, il n’existe aucune formulation d’olanzapine à action prolongée qui ne soit soumise à un plan de gestion des risques (Risk Evaluation and Mitigation Strategy – REMS) exigé par la FDA. Ce dispositif impose une administration dans un établissement de santé certifié ainsi qu’une période de surveillance de trois heures après l’injection. Dans l’étude de phase 3 SOLARIS, l’olanzapine LAI, administrée une fois par mois par injection sous-cutanée, a démontré un profil d’efficacité et de tolérance comparable à celui des formulations d’olanzapine actuellement disponibles, sans mettre en évidence la nécessité d’une surveillance post-injection.


« L’observance thérapeutique reste un défi majeur et un besoin médical non satisfait pour les personnes vivant avec une schizophrénie, en particulier celles traitées par olanzapine orale. Notre olanzapine injectable à libération prolongée, administrée par voie sous-cutanée, pourrait apporter une plus grande stabilité en offrant l’efficacité et la sécurité éprouvées de l’olanzapine sous la forme d’un traitement mensuel », a déclaré Eric Hughes, MD, PhD, vice-président exécutif R&D mondiale et directeur médical de Teva. « L’absence d’une formulation d’olanzapine à action prolongée viable a, pendant trop longtemps, limité les options thérapeutiques disponibles. Nous sommes impatients de travailler avec la FDA dans le cadre de l’examen de cette demande afin de contribuer à répondre à ce besoin médical non satisfait. »


« L'olanzapine sous forme quotidienne est l'un des antipsychotiques les plus couramment prescrits aux personnes atteintes de schizophrénie, et une formulation à libération prolongée pourrait mieux s'adapter à leur quotidien », a déclaré Christophe Douat, Directeur Général de Medincell. « À mesure que le recours aux traitements injectables à libération prolongée progresse, ils sont de plus en plus reconnus comme une option thérapeutique essentielle pour la prise en charge des troubles psychiatriques sévères. Le potentiel d’un traitement à libération prolongée pratique et adapté est donc considérable. »


La demande de mise sur le marché (NDA) pour l’Olanzapine LAI repose sur les résultats de l'essai SOLARIS de phase III, y compris les résultats à 56 semaines évaluant son efficacité, son innocuité et sa tolérance chez des participants âgés de 18 à 64 ans atteints de schizophrénie1. Les résultats ont démontré un profil d'efficacité et d'innocuité conforme à celui des formulations d'olanzapine actuellement disponibles1.


L’Olanzapine LAI est une injection sous-cutanée, expérimentale, mensuelle, à libération prolongée unique de deuxième génération, d'olanzapine, un antipsychotique atypique. Elle n'est actuellement approuvée par aucune autorité réglementaire pour quelque usage que ce soit.


L’Olanzapine LAI utilise SteadyTeq™, une technologie de copolymère propriétaire de Medincell qui assure une libération contrôlée, régulière et prolongée de l'olanzapine.


À propos de l’étude sur l’injection sous-cutanée d’olanzapine à libération prolongée (SOLARIS)


SOLARIS est une étude internationale, multicentrique, randomisée, en double aveugle, avec groupes parallèles et contrôle placebo, visant à évaluer l’efficacité, la sécurité et la tolérance de l’injection sous-cutanée à libération prolongée d’olanzapine chez des patients âgés de 18 à 64 ans atteints de schizophrénie1.


Pour la première période de l’étude (les 8 premières semaines), 675 patients ont été randomisés pour recevoir une injection sous-cutanée mensuelle d’olanzapine LAI (TEV-749) à faible, moyenne ou forte dose, ou un placebo, selon un ratio 1:1:1:11. Pour la deuxième période (les 48 semaines suivantes), les patients ayant terminé la première période ont été randomisés et répartis de manière équitable dans l’un des trois groupes de traitement par olanzapine LAI (TEV-749)1. Les visites de fin de traitement et de suivi ont eu lieu respectivement 4 et 8 semaines après l’administration de la dernière dose1.


L’objectif principal de l’étude de Phase 3 SOLARIS était d’évaluer l’efficacité de l’olanzapine LAI (TEV-749) chez des patients adultes atteints de schizophrénie1. Un objectif secondaire clé consistait à évaluer plus en détail son efficacité à partir de paramètres supplémentaires1. Un objectif secondaire de la deuxième période de l’étude était d’évaluer la sécurité et la tolérance de l’olanzapine LAI (TEV-749) chez les patients adultes1.


À propos de la schizophrénie


La schizophrénie est un trouble mental chronique, évolutif et gravement invalidant qui affecte la pensée, les émotions et le comportement2. Les patients présentent une variété de symptômes, pouvant inclure des délires, des hallucinations, un langage ou un comportement désorganisé, ainsi qu’une altération des capacités cognitives.,3,4,5


Environ 1 % de la population mondiale développera une schizophrénie au cours de sa vie, et 3,5 millions de personnes aux États-Unis sont actuellement diagnostiquées4,5. Bien que la schizophrénie puisse survenir à tout âge, l’âge moyen d’apparition se situe généralement à la fin de l’adolescence ou au début de la vingtaine pour les hommes, et à la fin de la vingtaine ou au début de la trentaine pour les femmes5.


L’évolution à long terme de la schizophrénie est marquée par des épisodes de rémission partielle ou complète entrecoupés de rechutes, souvent dans le cadre d’urgences psychiatriques nécessitant une hospitalisation4. Environ 80 % des patients connaissent plusieurs rechutes au cours des cinq premières années de traitement, chaque rechute entraînant un risque biologique de perte de fonction, de résistance au traitement et de modifications de la morphologie cérébrale.6,7,8


Les patients ne sont souvent pas conscients de leur maladie et de ses conséquences, ce qui contribue à la non-observance du traitement, à un taux élevé d’abandon et, in fine, à des coûts de santé directs et indirects significatifs liés aux rechutes et aux hospitalisations ultérieures.3,4,5,6,7,8


A propos de Medincell


Medincell est une société de licensing biopharmaceutique en phase clinique et commerciale qui développe des traitements injectables à action prolongée dans de nombreux domaines thérapeutiques. Nos traitements innovants visent à garantir le respect des prescriptions médicales, à améliorer l'efficacité et l'accessibilité des médicaments et à réduire leur empreinte environnementale.


Ils combinent des principes actifs avec nos technologies propriétaires BEPO®, qui contrôlent la libération d'un médicament à un niveau thérapeutique pendant plusieurs jours, semaines ou mois à partir de l'injection sous-cutanée ou locale d'un simple dépôt entièrement biorésorbable.


La rispéridone LAI est le premier traitement utilisant la technologie BEPO® à avoir été approuvé par la FDA, d'abord pour la schizophrénie en avril 2023, puis pour le trouble bipolaire I en octobre 2025. Il est commercialisé aux États-Unis par Teva sous le nom d'UZEDY® (la technologie BEPO est licenciée à Teva sous le nom de SteadyTeq™). La rispéridone LAI de Medincell a également été approuvée pour la schizophrénie au Canada et en Corée du Sud en 2025.


Une demande d’autorisation de mise sur le marché pour l’Olanzapine LAI en traitement mensuel de la schizophrénie chez l’adulte a été soumise à la FDA américaine en décembre 2025 par le partenaire de Medincell, Teva.


Notre pipeline comprend de nombreux candidats médicaments innovants à différents stades de développement, de la formulation aux essais cliniques de phase 3. Nous collaborons avec des entreprises pharmaceutiques de premier plan et des fondations pour améliorer la santé dans le monde grâce à de nouvelles options de traitement.


Basée à Montpellier, Medincell emploie plus de 140 personnes représentant plus de 25 nationalités différentes.


medincell.com


UZEDY® et SteadyTeq™ sont des marques déposées de Teva Pharmaceuticals


Ce communiqué de presse peut contenir des déclarations prospectives, notamment concernant la progression des essais cliniques de la Société. Même si la Société considère que ses prévisions sont fondées sur des hypothèses raisonnables, toutes déclarations autres que des déclarations de faits historiques que pourrait contenir ce communiqué de presse relatives à des événements futurs sont sujettes à des changements sans préavis, à des facteurs que la Société ne maîtrise pas et aux capacités financières de la Société.


Ces déclarations peuvent inclure, sans que cette liste soit limitative, toutes déclarations commençant par, suivies par ou comprenant des mots ou expressions tels que « objectif », « croire », « prévoir », « viser », « avoir l’intention de », « pouvoir », « anticiper », « estimer », « planifier », « projeter », « devra », « peut avoir », « probablement », « devrait », « pourrait » et d’autres mots et expressions de même sens ou employés à la forme négative. Les déclarations prospectives sont sujettes à des risques intrinsèques et à des incertitudes hors du contrôle de la Société qui peuvent, le cas échéant, entraîner des différences notables entre les résultats, performances ou réalisations réels de la Société et ceux anticipés ou exprimés explicitement ou implicitement par lesdites déclarations prospectives.


Une liste et une description de ces risques, éventualités et incertitudes figurent dans les documents déposés par la Société auprès de l'Autorité des marchés financiers (l'« AMF ») conformément à ses obligations réglementaires, notamment le document d’enregistrement universel de la Société, déposé auprès de l'AMF le 29 juillet 2025 sous le numéro D. 25-0580 (le « Document d'enregistrement universel »), ainsi que dans les documents et rapports qui seront publiés ultérieurement par la Société. L'attention des lecteurs est notamment attirée sur la section intitulée « Facteurs de risques » à la page 30 et suivantes 26 du Document d'enregistrement.


Les déclarations prospectives faites par ou au nom de la Société ne sont valables qu'à la date à laquelle elles sont faites. Sauf si la loi l'exige, la Société ne s'engage aucunement à mettre à jour publiquement ces déclarations prospectives ou à mettre à jour les raisons pour lesquelles les résultats réels pourraient différer sensiblement de ceux anticipés dans les déclarations prospectives, y compris dans le cas où de nouvelles informations seraient disponibles. La mise à jour par la Société d'une ou plusieurs déclarations prospectives n'implique pas que la Société procédera à d'autres mises à jour de ces déclarations prospectives ou d'autres déclarations prospectives. Les lecteurs sont priés de ne pas se fier indûment à ces déclarations prospectives.


Le présent communiqué de presse est publié à titre informatif uniquement. Les informations qu'il contient ne constituent pas une offre de vente ni une sollicitation d'offre d'achat ou de souscription d'actions de la Société dans quelque juridiction que ce soit, en particulier en France. De même, le présent communiqué de presse ne constitue pas un conseil en investissement et ne doit pas être considéré comme tel. Il n'est pas lié aux objectifs d'investissement, à la situation financière ou aux besoins spécifiques d'un destinataire quelconque. Il ne doit pas priver les destinataires de la possibilité d'exercer leur propre jugement. Toutes les opinions exprimées dans le présent document sont susceptibles d'être modifiées sans préavis. La diffusion du présent communiqué de presse peut être soumise à des restrictions légales dans certaines juridictions.


1 Données internes. Parsippany, NJ: Teva Neuroscience, Inc.

2 L’acceptation d’une demande de mise sur le marché par la FDA américaine, ouvre une période d’environ 8 mois pour un examen standard du dossier.

3 Substance Abuse and Mental Health Services Administration. Schizophrenia. https://www.samhsa.gov/mental-health/schizophrenia.

4 Velligan DI, Rao S. The Epidemiology and Global Burden of Schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. https://doi.org/10.4088/JCP.MS21078COM5.

5 Wander C. (2020). Schizophrenia: Opportunities to Improve Outcomes and Reduce Economic Burden Through Managed Care. The Am J Manag Care. 26(3 Suppl), S62–S68. https://doi.org/10.37765/ajmc.2020.43013.

6 Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Dis. Treat., 14, 205–223.

7 Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13, 50.

8 Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. The Am J Psychiatry, 170(6), 609–615.

Consultez la version source sur businesswire.com : https://www.businesswire.com/news/home/20260220195437/fr/
David Heuzé

Head of Corporate and Financial Communications, and ESG

david.heuze@MedinCell.com / +33 (0)6 83 25 21 86


Grace Kim

Chief Strategy Officer, U.S. Finance

Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in AdultsFebruary 20, 2026 3:37 PM
Business Wire

Olanzapine long-acting injectable suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1



If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1



Teva is committed to advancing this innovative treatment option and further building on its differentiated LAI franchise and scientific leadership in complex neurological conditions as it drives forward its Pivot to Growth strategy



Regulatory News:


Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 is designed to improve real-world treatment adherence and help patients maintain long-term stability, with the goal of addressing a critical treatment gap for people living with schizophrenia.


Currently, there is no long-acting olanzapine formulation without an FDA-required Risk Evaluation and Mitigation Strategy (REMS), which mandates administration in a certified healthcare facility and requires a 3-hour post-injection monitoring period. In the Phase 3 SOLARIS trial, TEV-'749 administered as a once-monthly subcutaneous injection demonstrated an efficacy and safety profile consistent with currently available olanzapine formulations and showed no evidence for the need for post-injection monitoring.


“Treatment adherence remains a major challenge and unmet need for people living with schizophrenia, including many who rely on oral forms of olanzapine. TEV-'749, our investigational subcutaneously delivered olanzapine LAI, has the potential to help provide stability by offering the proven efficacy and safety of olanzapine as a once-monthly treatment,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “For too long, the lack of a viable long-acting olanzapine formulation has limited the options available to these individuals, and we look forward to working with the FDA on the review of this NDA for TEV-'749 to help address this gap in care.”


“Daily olanzapine is one of the most widely prescribed antipsychotics for people living with schizophrenia, and this long-acting formulation may better fit into their lives,” said Christophe Douat, CEO of Medincell. “As experience with long-acting injectables continues to grow, they are increasingly recognized as an important treatment option in serious psychiatric conditions. The potential reach of a practical long-acting option is significant.”


The NDA for TEV-'749 is based on results from the Phase 3 SOLARIS trial, including Week 56 results studying its efficacy, safety and tolerability in participants aged 18 to 64 living with schizophrenia.1 The results demonstrated an efficacy and safety profile consistent with currently available olanzapine formulations.1


TEV-'749 is an investigational once-monthly subcutaneous LAI of the second-generation atypical antipsychotic olanzapine. It is not approved by any regulatory authority for any use at this time.


TEV-'749 utilizes SteadyTeq™, a copolymer technology proprietary to Medincell that provides a controlled steady, sustained release of olanzapine.


About Subcutaneous OLAnzapine Extended-Release Injection Study (SOLARIS)


SOLARIS is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of olanzapine extended-release injectable suspension for subcutaneous use as a treatment in patients (ages 18-64 years) with schizophrenia.1 For period one of the study (first 8 weeks), 675 patients were randomized to receive a subcutaneous injection of once-monthly olanzapine LAI (TEV-'749) (low, medium or high dose) or placebo in a 1:1:1:1 ratio.1 For period two (next 48 weeks), patients who completed period one were randomized and equally allocated to one of the three olanzapine LAI (TEV-'749) treatment groups.1 The end-of-treatment and follow-up visits were 4 and 8 weeks after administration of the last treatment dose, respectively.1 The primary objective of the Phase 3 SOLARIS study was to evaluate the efficacy of olanzapine LAI (TEV-'749) in adult patients with schizophrenia.1 A key secondary objective was to further evaluate the efficacy of olanzapine LAI (TEV-'749) based on additional parameters in adult patients with schizophrenia.1 A secondary objective of period two of the study was to evaluate the safety and tolerability of olanzapine LAI (TEV-'749) in adult patients with schizophrenia.1


About Schizophrenia


Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.2 Patients experience an array of symptoms, which may include delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability.2,3,4 Approximately 1% of the world’s population will develop schizophrenia in their lifetime, and 3.5 million people in the U.S. are currently diagnosed with the condition.3,4 Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 20s for men, and the late 20s to early 30s for women.4 The long-term course of schizophrenia is marked by episodes of partial or full remission broken by relapses that often occur in the context of psychiatric emergency and require hospitalization.4 Approximately 80% of patients experience multiple relapses over the first five years of treatment, and each relapse carries a biological risk of loss of function, treatment refractoriness, and changes in brain morphology.5,6,7 Patients are often unaware of their illness and its consequences, contributing to treatment nonadherence, high discontinuation rates, and ultimately, significant direct and indirect healthcare costs from subsequent relapses and hospitalizations.2,3,4,5,6,7


About Teva


Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.


Cautionary Note Regarding Forward-Looking Statements


This Press Release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop olanzapine LAI (TEV-‘749) for the treatment of adult patients diagnosed with schizophrenia and to obtain regulatory FDA approval; our ability to successfully compete in the marketplace, including our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.



Data on file. Parsippany, NJ: Teva Neuroscience, Inc.



Substance Abuse and Mental Health Services Administration. Schizophrenia. https://www.samhsa.gov/mental-health/schizophrenia. Accessed February 2026.



Velligan DI, Rao S. The Epidemiology and Global Burden of Schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. https://doi.org/10.4088/JCP.MS21078COM5.



Wander C. (2020). Schizophrenia: Opportunities to Improve Outcomes and Reduce Economic Burden Through Managed Care. The Am J Manag Care. 26(3 Suppl), S62–S68. https://doi.org/10.37765/ajmc.2020.43013.



Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Dis. Treat., 14, 205–223.



Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13, 50.



Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. The Am J Psychiatry, 170(6), 609–615.



About Medincell


Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260220354072/en/
Teva Media Inquiries:

TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries:

TevaIR@Tevapharm.com


Medincell

communication@medincell.com


Original: Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

ELTP > 17.73% gain today according to E-trade...$.0667 gained back ...great day and hopefully a blockbuster week ahead with record breaking quarterly earnings again and merger and acquisition news from possibly TEVA.
Potential Elite Pharmaceuticals (ELTP) Buyers...From Grok AI   

Which pharmaceuticals companies are still at risk with the looming pharma tariff and would significantly benefit from acquiring Elite Pharmaceuticals at this time?   

Indian generics giants with heavy U.S. market reliance remain most at risk despite broad exemptions for finished generic drugs. As of February 2026, the Trump administration’s policy imposes 100% tariffs on imported branded/patented pharmaceuticals (unless companies commit to U.S. manufacturing), with generics largely spared. However, risks persist from:   •  Potential expansion to specialty/complex generics   •  APIs & intermediates (China supplies ~40% of global APIs; India depends heavily on China)   •  Ongoing Section 232 investigations   •  Competitive pressure and supply chain vulnerabilities   Acquiring Elite Pharmaceuticals (ELTP) would provide these companies immediate tariff-resilient U.S. manufacturing (Northvale, NJ DEA/FDA-approved facility), ~$170M annualized revenue (primarily ADHD generics), and quota capacity in high-demand categories.   Top Companies Still at Risk + High Benefit from Acquiring Elite   
1.  Sun Pharmaceutical Industries (India)   
Largest Indian pharma exporter to the U.S. (~35%+ of revenue often tied to U.S. generics/specialty). Highly exposed to any tariff broadening or API cost hikes.   
Benefit: Elite adds instant U.S. capacity + ADHD portfolio (Adderall IR/XR, Vyvanse generics) to complement Sun’s complex generics focus. Low-cost entry for reshoring without new builds.   
2.  Dr. Reddy’s Laboratories (India)   
Highest U.S. revenue exposure among majors (~40-47%). Vulnerable if tariffs extend to specialty products or APIs.   
Benefit: Elite’s fully domestic ops + controlled-release tech + pipeline (e.g., potential Concerta generic, anticoagulant) would accelerate U.S. growth and hedge risks.   
3.  Lupin (India)   
Significant U.S. generics exposure (~35-40% revenue). Faces price erosion and indirect tariff pressure.   
Benefit: Acquiring Elite delivers ready-made U.S. ADHD manufacturing scale amid shortages/quota increases, strengthening Lupin’s specialty generics position.   
4.  Teva Pharmaceutical Industries (Israel)   
World’s largest generics maker with substantial U.S. sales; relies on global (including Asian) supply chains.   
Benefit: Elite offers pure U.S.-based controlled substances capacity, synergies in pain/ADHD, and tariff-proof production for its massive U.S. generics business.   
5.  Aurobindo Pharma or Zydus Lifesciences (India)   
High U.S. generics dependence; similar API/import vulnerabilities as peers.   
Benefit: Provides quick U.S. footprint expansion and diversification into high-margin ADHD/ER products.   Key Context   •  Generics exemptions + pricing deals have limited immediate impact, but downside “flare-up” risk remains high.      •  Indian firms supply ~45% of U.S. generic volumes; U.S. market = 30-47% of their revenue for top players.     •  Elite’s appeal: Turnkey U.S. facility + strong FY2026 momentum (~$170-180M projected revenue) + low valuation makes it a fast reshoring play.   M&A likelihood for Elite in 2026 is moderately high (~60-70% per prior analysis), but no deals are confirmed yet. Monitor Q3 earnings (Feb 12, 2026) for updates. These Indian players stand to gain the most strategically from an acquisition.

Do you think TEVA should acquire U.S.-based drug manufacturer, Elite Pharmaceuticals (ELTP), to mitigate the looming traiff cost with some of it drugs manufactured outside of the U.S.?
Potential Buyers...From Grok AI 

Which pharmaceuticals companies are still at risk with the looming pharma tariff and would significantly benefit from acquiring Elite Pharmaceuticals at this time? 


Indian generics giants with heavy U.S. market reliance remain most at risk despite broad exemptions for finished generic drugs. As of February 2026, the Trump administration’s policy imposes 100% tariffs on imported branded/patented pharmaceuticals (unless companies commit to U.S. manufacturing), with generics largely spared. However, risks persist from: 
•  Potential expansion to specialty/complex generics 
•  APIs & intermediates (China supplies ~40% of global APIs; India depends heavily on China) 
•  Ongoing Section 232 investigations 
•  Competitive pressure and supply chain vulnerabilities 
Acquiring Elite Pharmaceuticals (ELTP) would provide these companies immediate tariff-resilient U.S. manufacturing (Northvale, NJ DEA/FDA-approved facility), ~$170M annualized revenue (primarily ADHD generics), and quota capacity in high-demand categories. 
Top Companies Still at Risk + High Benefit from Acquiring Elite 

1.  Sun Pharmaceutical Industries (India) 

Largest Indian pharma exporter to the U.S. (~35%+ of revenue often tied to U.S. generics/specialty). Highly exposed to any tariff broadening or API cost hikes. 

Benefit: Elite adds instant U.S. capacity + ADHD portfolio (Adderall IR/XR, Vyvanse generics) to complement Sun’s complex generics focus. Low-cost entry for reshoring without new builds. 

2.  Dr. Reddy’s Laboratories (India) 

Highest U.S. revenue exposure among majors (~40-47%). Vulnerable if tariffs extend to specialty products or APIs. 

Benefit: Elite’s fully domestic ops + controlled-release tech + pipeline (e.g., potential Concerta generic, anticoagulant) would accelerate U.S. growth and hedge risks. 

3.  Lupin (India) 

Significant U.S. generics exposure (~35-40% revenue). Faces price erosion and indirect tariff pressure. 

Benefit: Acquiring Elite delivers ready-made U.S. ADHD manufacturing scale amid shortages/quota increases, strengthening Lupin’s specialty generics position. 

4.  Teva Pharmaceutical Industries (Israel) 

World’s largest generics maker with substantial U.S. sales; relies on global (including Asian) supply chains. 

Benefit: Elite offers pure U.S.-based controlled substances capacity, synergies in pain/ADHD, and tariff-proof production for its massive U.S. generics business. 

5.  Aurobindo Pharma or Zydus Lifesciences (India) 

High U.S. generics dependence; similar API/import vulnerabilities as peers. 

Benefit: Provides quick U.S. footprint expansion and diversification into high-margin ADHD/ER products. 
Key Context 
•  Generics exemptions + pricing deals have limited immediate impact, but downside “flare-up” risk remains high.    
•  Indian firms supply ~45% of U.S. generic volumes; U.S. market = 30-47% of their revenue for top players.   
•  Elite’s appeal: Turnkey U.S. facility + strong FY2026 momentum (~$170-180M projected revenue) + low valuation makes it a fast reshoring play. 
M&A likelihood for Elite in 2026 is moderately high (~60-70% per prior analysis), but no deals are confirmed yet. Monitor Q3 earnings (Feb 12, 2026) for updates. These Indian players stand to gain the most strategically from an acquisition.

Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic MigraineFebruary 4, 2026 8:05 AM
PR Newswire (Canada)

Health Canada approves PrAJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 years and weighing at least 45 kg.PrAJOVY® increases availability across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention in adults.This approval marks an important step in enhancing the impact of PrAJOVY® beyond adults since its Canadian approval in 2020, and underscores Teva's ongoing efforts to advance and address neurological challenges.TORONTO, Feb. 4, 2026 /CNW/ - Teva Canada Limited (Teva Canada) announced today that Health Canada has approved an expanded indication for PrAJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 years and weighing at least 45 kg. With this approval, PrAJOVY® becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for eligible pediatric patients, marking a meaningful advancement in expanding preventive treatment options for those living with migraine.







Migraine is a neurological disease that significantly impacts children and adolescents leading to missed school, reduced social participation, and wide-ranging effects on family life. With this approval, PrAJOVY® now offers a new, once-monthly preventive option to help reduce the frequency of migraine attacks for eligible pediatric patients."Migraine has a profound impact on children and teens, yet pediatric patients have historically had very few preventive treatment options", said Wendy Gerhart, Executive Director of Migraine Canada. "We welcome this approval as a meaningful step forward for families navigating this challenging condition. Having additional, evidence-based choices matters and may make a measurable difference in the day-to-day lives of young people living with migraine."Health Canada's approval of this indication is based on the results of Phase 3 SPACE trial, which demonstrated that fremanezumab significantly reduced monthly migraine days and monthly headache days versus placebo over a 12–week period in pediatric patients with episodic migraine and showed a safety profile consistent with adults.1"As an investigator in the clinical study that supported this approval, I've seen firsthand the meaningful impact fremanezumab may have for young people living with episodic migraine", said Dr. Daniela Pohl, MD, PhD, Professor of Pediatric Neurology at the Children's Hospital of Eastern Ontario. "This is an important advancement for Canadian children and adolescents who have long lacked evidence-based preventive options. Having AJOVY available to this population gives clinicians and families a targeted therapy that can help reduce migraine burden and improve day-to-day well-being."We are proud to bring this important advancement to pediatric migraine care in Canada," said Fabien Paquette, General Manager of Teva Canada. "This approval reflects Teva's commitment to helping patients across all stages of life, and to ensuring families have innovative therapies backed by strong clinical science. Expanding the availability of AJOVY to younger Canadians underscores our long-standing dedication to neurological health and to closing gaps in care.About PrAJOVY®
PrAJOVY® is indicated for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 years and weighing at least 45 kg. PrAJOVY® is available as a 225 mg/1.5 mL single dose injection in a pre-filled autoinjector or in a pre-filled syringe. PrAJOVY® can be administered either by a healthcare professional or at home by a patient 13 years of age or older or caregiver. No starting dose is required to begin treatment.About SPACE
SPACE is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing the efficacy, safety and tolerability of subcutaneous administration of fremanezumab versus placebo over a 12–week period for the preventive treatment of episodic migraine in 237 pediatric patients aged 6 to 17 years.About Teva Canada
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is proud to celebrate 60 years of serving the health of Canadians. As one of the world's largest suppliers of generic, biosimilar, and innovative medicines, we are all in for better health — committed to delivering reliable, high-quality treatments. With facilities in Markham, Stouffville, Toronto, and Montréal, we employ over 850 people and manufacture 70% of the medicines we sell in Canada locally, reinforcing our commitment to accessibility and supporting the Canadian economy. Learn more at www.tevacanada.com.Cautionary Note Regarding Forward–Looking Statements
This release includes forward–looking statements that are based on Teva's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include regulatory, market, and commercial factors, as well as those described in Teva's publicly filed reports. Forward–looking statements speak only as of the date of this release, and Teva undertakes no obligation to update them except as required by law_____________________________1 Hershey, A. D., Szperka, C. L., Barbanti, P., Pozo–Rosich, P., Bittigau, P., Barash, S., Bryson, J., Kessler, Y., Schwartz, Y. C., Campos, V. R., & Ning, X. (2026). Fremanezumab in Children and Adolescents with Episodic Migraine. New England Journal of Medicine.










SOURCE Teva Canada

Original: Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Teva Canada annonce l'approbation de l'indication élargie de [Pr]AJOVY[MD] (frémanézumab, solution pour injection sous cutanée), le premier traitement préventif anti-CGRP indiqué pour la migraine épisodique pédiatriqueFebruary 4, 2026 8:05 AM
PR Newswire (Canada)

Santé Canada approuve PrAJOVYMD (frémanézumab, solution pour injection sous-cutanée) pour la prévention de la migraine épisodique (moins de 15 jours de migraine par mois) chez les patients pédiatriques de 6 à 17 ans et pesant au moins 45 kg.PrAJOVYMD élargit l'accès dans tous les groupes d'âge en tant que premier et seul antagoniste du peptide lié au gène de la calcitonine (CGRP) approuvé pour la prévention de la migraine épisodique pédiatrique et la prévention de la migraine chez les adultes.Cette approbation marque une étape importante dans l'élargissement de l'impact de PrAJOVYMD au delà de la population adulte depuis son approbation au Canada en 2020 et souligne les efforts continus de Teva pour faire progresser la neurologie et relever les défis inhérents.TORONTO, le 4 févr. 2026 /CNW/ - Teva Canada Limitée (Teva Canada) a annoncé aujourd'hui que Santé Canada a approuvé une indication élargie pour PrAJOVYMD (frémanézumab, solution pour injection sous-cutanée) destinée à prévenir la migraine épisodique (moins de 15 jours de migraine par mois) chez les patients pédiatriques âgés de 6 à 17 ans et pesant au moins 45 kg. Avec cette approbation, PrAJOVYMD devient le premier et seul antagoniste du peptide lié au gène de la calcitonine (CGRP) indiqué pour les patients pédiatriques admissibles, ce qui marque un progrès significatif dans l'élargissement des choix thérapeutiques préventifs pour les personnes vivant avec la migraine.







La migraine est une maladie neurologique qui a un impact significatif sur les enfants et les adolescents, entraînant des absences scolaires, une participation sociale réduite et des effets variés sur la vie familiale. Grâce à cette approbation, PrAJOVYMD offre désormais un nouveau choix thérapeutique préventif à administration mensuelle qui pourra contribuer à réduire la fréquence des crises de migraine chez les patients pédiatriques admissibles.« La migraine a un impact profond sur les enfants et les adolescents; pourtant, les patients pédiatriques ont disposé historiquement de très peu de choix thérapeutiques préventifs, a déclaré Wendy Gerhart, directrice générale de Migraine Canada. Nous accueillons favorablement cette approbation, qui représente une avancée importante pour les familles confrontées à cette affection tenace. Des choix additionnels fondés sur des données probantes sont importants et peuvent avoir une influence appréciable sur la vie quotidienne des jeunes vivant avec la migraine. »L'approbation de cette indication par Santé Canada repose sur les résultats de l'essai de phase 3 SPACE, qui a démontré que le frémanézumab réduisait de manière significative le nombre de jours mensuels de migraine et de céphalées par rapport au placebo sur une période de 12 semaines chez les patients pédiatriques atteints de migraine épisodique, tout en présentant un profil d'innocuité cohérent avec le profil observé chez les adultes1.« En tant qu'investigatrice de l'étude clinique ayant soutenu cette approbation, j'ai pu constater directement l'impact significatif que le frémanézumab peut avoir chez les jeunes vivant avec la migraine épisodique, a déclaré la Dre Daniela Pohl, MD, Ph. D., professeure de neurologie pédiatrique au Children's Hospital of Eastern Ontario. Il s'agit d'une avancée importante pour les enfants et les adolescents au Canada, qui ont longtemps manqué de choix préventifs fondés sur des données probantes. Le fait qu'AJOVY soit maintenant accessible à cette population offre aux cliniciens et aux familles un traitement ciblé qui pourra aider à réduire le fardeau de la migraine et améliorer le bien-être au quotidien. »« Nous sommes fiers d'apporter cette avancée importante aux soins de la migraine pédiatrique au Canada, a affirmé Fabien Paquette, directeur général de Teva Canada. Cette approbation reflète l'engagement de Teva à aider les patients à toutes les étapes de la vie et à offrir aux familles des traitements innovants appuyés par une science clinique robuste. L'élargissement de l'accès à PrAJOVYMD pour les jeunes Canadiens souligne notre dévouement de longue date à la santé neurologique et la réduction des lacunes en matière de soins. »À propos de PrAJOVYMDPrAJOVYMD est indiqué pour la prévention de la migraine épisodique (moins de 15 jours de migraine par mois) chez les patients pédiatriques de 6 à 17 ans pesant au moins 45 kg. PrAJOVYMD est offert sous forme d'injection unidose de 225 mg/1,5 mL dans un auto-injecteur prérempli ou une seringue préremplie. PrAJOVYMD peut être administré par un professionnel de la santé ou à domicile par un patient de 13 ans ou plus, ou par un aidant. Aucune dose initiale n'est requise pour amorcer le traitement.À propos de l'essai SPACESPACE est une étude multicentrique randomisée à double insu contrôlée par placebo, menée selon un modèle en groupes parallèles, comparant l'efficacité, l'innocuité et la tolérabilité du frémanézumab administré par voie sous-cutanée à celles du placebo sur une période de 12 semaines pour le traitement préventif de la migraine épisodique chez 237 patients pédiatriques âgés de 6 à 17 ans.À propos de Teva CanadaTeva Canada Limitée, une filiale de Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA), est fière de célébrer 60 ans au service de la santé des Canadiens. En tant que l'un des plus importants fournisseurs mondiaux de médicaments génériques, biosimilaires et innovants, nous avons tous à cœur d'améliorer la santé, et nous nous engageons à offrir des traitements fiables de haute qualité. Avec des installations à Markham, Stouffville, Toronto et Montréal, nous employons plus de 850 personnes et fabriquons localement 70 % des médicaments que nous vendons au Canada, renforçant ainsi notre engagement envers l'accessibilité et l'économie canadienne. Pour en savoir plus : www.tevacanada.com.Note concernant les énoncés prospectifsLe présent communiqué contient des énoncés prospectifs qui sont basés sur les attentes actuelles de Teva et qui peuvent comporter des risques et incertitudes pouvant entraîner des résultats réels qui diffèrent sensiblement des énoncés. Ces risques incluent des facteurs réglementaires, des facteurs commerciaux et des facteurs liés au marché, de même que les facteurs décrits dans les documents publics déposés par Teva. Les énoncés prospectifs ne valent qu'en date du présent communiqué, et Teva n'assume aucune obligation de les mettre à jour, sauf si la loi l'exige.
_____________________________________
1 Hershey, A. D., Szperka, C. L., Barbanti, P., Pozo-Rosich, P., Bittigau, P., Barash, S., Bryson, J., Kessler, Y., Schwartz, Y. C., Campos, V. R., & Ning, X. (2026). Fremanezumab in Children and Adolescents with Episodic Migraine. New England Journal of Medicine.










SOURCE Teva Canada

Original: Teva Canada annonce l'approbation de l'indication élargie de [Pr]AJOVY[MD] (frémanézumab, solution pour injection sous cutanée), le premier traitement préventif anti-CGRP indiqué pour la migraine épisodique pédiatrique

Teva Canada Announces Strategic Partnership with Novartis Canada to Relaunch Mayzent® for Multiple Sclerosis Patients in Canada

https://finance.yahoo.com/news/teva-canada-announces-strategic-partnership-130500610.html

TORONTO, Feb. 2, 2026 /CNW/ - Teva Canada Limited (Teva Canada) is announcing a new commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. (Novartis Canada) for Mayzent® (siponimod), an innovative oral treatment for secondary progressive multiple sclerosis (SPMS) with active disease. Under the partnership, Teva Canada will assume exclusive responsibility for the promotion, distribution, and commercialization of Mayzent® in Canada.

This collaboration leverages Teva's established central nervous system (CNS) expertise and national commercial infrastructure, ensuring continued access to Mayzent® for Canadian patients and healthcare professionals. The agreement is designed to maximize the reach and impact of Mayzent®, building on Teva's established history with neurologists and MS specialists across the country.
"This is about more than a product - it's about people," said Fabien Paquette, General Manager, Teva Canada. "Through this partnership, we are reaffirming our dedication to the MS community and to patient-centred care. Teva Canada is proud to lead with purpose, ensuring access and support for those who need it most. We are all in for better health."

"This agreement reflects our shared responsibility to support people living with MS," said Dimitri Gitas, Country President, Novartis Canada "Through this partnership, we're strengthening support for Canadians living with multiple sclerosis and advancing better health outcomes nationwide."

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

https://finance.yahoo.com/news/teva-royalty-pharma-enter-agreement-220000891.html

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408

TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac disease

Funding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

https://finance.yahoo.com/news/p-global-ratings-upgrades-teva-133600986.html

The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.

Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from stable

S&P upgraded Teva to BB+ from BB, with a stable outlook

TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer credit rating to ‘BB+’ from ‘BB’, with a stable outlook, and that Moody's Ratings Agency ("Moody's") affirmed Teva's B1a rating and revised Teva's outlook to positive from stable. These upgrades mark another significant milestone in Teva’s journey toward achieving investment-grade status.

Glenview Capital Management, LLC increased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 868,457 shares in the third quarter, adding approximately $71.98 million in value, according to a November 14, 2025, SEC filing.

https://finance.yahoo.com/news/glenview-doubles-down-teva-stock-155037560.html

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

https://finance.yahoo.com/news/teva-pharmaceuticals-submits-drug-application-130000833.html

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population1

Olanzapine LAI is designed to help support real-world adherence and improved stability, with the goal of addressing a critical treatment gap for people living with schizophrenia1

Teva is committed to advancing this innovative treatment option and further build on its differentiated LAI franchise

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

https://finance.yahoo.com/news/teva-receives-european-commission-approvals-131000745.html

🌱 Chronic Pain (Non-Cancer)
Cannabis: Patients turn to cannabis for neuropathic pain, migraines, and fibromyalgia, valuing its natural profile.

Pharma/Biotech: Opioids, gabapentin, and lab-engineered pain modulators are the standard.

Competition: Cannabis is marketed as “nature’s painkiller,” while pharma stresses controlled dosing and patent-protected molecules. $TEVA $WEED $MSOS $TLRY $CGC

$TEVA $24.355 ^3.895 (19.04%)
Nice!

Teva Pharma Surges On Its Big Sales Beat, Austedo Guidance Hike.

https://finance.yahoo.com/m/33072f88-68e4-379d-a857-59a3cc60b14b/teva-pharma-surges-on-its-big.html

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of ‘The Other TD,’ a disease education campaign leveraging the broad recognition of football touchdowns to raise awareness and understanding of a lesser-known TD – tardive dyskinesia. The goal of the campaign is to help undiagnosed Americans living with TD, and their care partners, recognize symptoms and take action by having conversations with their healthcare provider. Terrell Davis, known for his iconic initials, “TD,” and for scoring dozens of touchdowns in his career, is partnering with Teva to shine a light on ‘The Other TD’.
15.4 million Americans are living with a serious mental illness,8 such as bipolar disorder, major depressive disorder, or schizophrenia, with many using antipsychotic medications to treat these conditions. While these treatments can provide much needed relief to patients, 25% of those taking certain mental health treatments may develop uncontrollable movements, known as TD.2,9,10 This disorder can make everyday tasks like eating, getting dressed, and walking difficult,1-2 but it can be treated without interrupting your mental health progress.4

“As someone who has faced my own mental health challenges, I understand the importance of speaking out and providing support for those encountering similar obstacles,” said Terrell Davis, Pro Football Hall of Famer and 2x champion. “Because of this, I am honored to be partnering with Teva to use my name and platform to increase awareness around TD and empower those who might be struggling to learn more and seek treatment.”

‘The Other TD’ provides educational information about TD, including how to recognize symptoms and its physical, emotional, social, and functional impacts. Additional resources for patients about treatment options and tips for care partners are also available.

Despite its estimated impact on 785,000 Americans, only approximately 15% receive a formal TD diagnosis and only 5% receive treatment.3 Underdiagnosis is especially high among younger individuals, men, and racial and ethnic minority groups, including Black Americans who have lower rates of formal TD diagnoses despite their TD movements being recognized an average of seven years prior.5-7 The effects of TD, however, are not solely physical. In fact, three out of four people who have TD say it severely impacts how they function, feel, and interact with others.1-3

“‘The Other TD’ emphasizes our commitment to TD patients seeking treatment and support, to those who may have TD but not know it, and to care partners looking to support their loved ones,” said Heather DeMyers, Vice President, U.S. Innovative Medicines Marketing at Teva. “Ultimately, we want individuals to know if they are suffering from the impacts of TD—they are not alone. While TD may impact their daily life, there are effective treatment options available that don’t have to interfere with their mental health journey.”

Please visit TheOtherTD.com to learn more about typical TD symptoms and potential treatment options.

https://apnews.com/article/fda-recall-prazosin-teva-blood-cancer-ce6338047a5f628300cc95e0eeb89b0b

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

https://finance.yahoo.com/news/teva-host-conference-call-discuss-203000372.html

TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California.


Teva will also host a conference call for analysts and investors on Monday, September 22, 2025, at 11:00 a.m. ET to discuss these data.

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

August 28 2025 - 8:30AM

Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the FDA approval and U.S. launch of a generic version of Saxenda®1 (liraglutide injection).
“With this approval, and by launching a generic for Saxenda® (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Teva. “This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva's diverse complex generics portfolio, demonstrating once again our proven ability to sustain a world class Generics Powerhouse.”

Saxenda® had annual sales of $165 million as of June 2025.2

What is Liraglutide Injection?

Liraglutide Injection is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:

Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity.
Adults with overweight in the presence of at least one weight-related comorbid condition.
Liraglutide injection should be used with a reduced calorie diet and increased physical activity.
Liraglutide injection is not recommended for people who also take liraglutide or other medicines called glucagon-like peptide-1 (GLP-1) receptor agonists.
It is not known if liraglutide injection is safe and effective in children under 12 years of age.
It is not known if liraglutide injection is safe and effective in children aged 12 to 17 years with type 2 diabetes.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about liraglutide injection?
Serious side effects may happen in people who take liraglutide injection, including:
Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rats and mice, liraglutide injection and medicines that work like liraglutide injection caused thyroid tumors, including thyroid cancer. It is not known if liraglutide injection will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.
Do not use liraglutide injection if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Who should not take liraglutide injection?
Do not receive liraglutide injection if:

you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
you have had a serious allergic reaction to liraglutide or any of the ingredients in liraglutide injection. See “What are the possible side effects of liraglutide injection?” for symptoms of a serious allergic reaction.
Before taking liraglutide injection tell your healthcare provider about all of your medical conditions, including if you:

have or have had problems with your pancreas
have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food.
are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).
have or have had depression or suicidal thoughts, or mental health issues.
are breastfeeding or plan to breastfeed. It is not known if liraglutide passes into your breast milk. You and your healthcare provider should decide if you will use liraglutide injection or breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Liraglutide injection may affect the way some medicines work and some other medicines may affect the way liraglutide injection works.

Tell your healthcare provider if you take diabetes medicines, especially insulin and sulfonylurea medicines. Talk with your healthcare provider if you are not sure if you take any of these medicines. Know the medicines you take. Keep a list to show your healthcare provider and pharmacist when you get a new medicine.

What are the possible side effects of liraglutide injection?
Liraglutide Injection may cause serious side effects, including:

inflammation of the pancreas (pancreatitis). Stop using liraglutide injection and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your stomach area (abdomen) to your back
increased risk of low blood sugar (hypoglycemia) in adults with type 2 diabetes especially those who also take medicines to treat type 2 diabetes mellitus such as an insulin or a sulfonylureas and in children who are 12 years of age and older without type 2 diabetes mellitus. Low blood sugar in patients with adults with type 2 diabetes and in children without type 2 diabetes mellitus who receive liraglutide injection can be both a serious and common side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar. You should check your blood sugar before you start taking liraglutide injection and while you take liraglutide injection.
Signs and symptoms of low blood sugar may include:
dizziness or light-headedness
sweating
confusion or drowsiness
headache
blurred vision
slurred speech
shakiness
fast heartbeat
anxiety, irritability, or mood changes
hunger
weakness
feeling jittery
Talk to your healthcare provider about how to recognize and treat low blood sugar. You should check your blood sugar before you start taking liraglutide injection and while you take liraglutide injection.

increased heart rate. Liraglutide injection can increase your heart rate while you are at rest. Your healthcare provider should check your heart rate while you take liraglutide injection. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes.
dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away
severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use liraglutide injection. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
serious allergic reactions. Stop using liraglutide injection, and get medical help right away if you have any symptoms of a serious allergic reaction including:
swelling of your face, lips, tongue, or throat
problems breathing or swallowing
severe rash or itching
fainting or feeling dizzy
very rapid heartbeat

gallbladder problems. Liraglutide injection may cause gallbladder problems including gallstones. Some gallbladder problems need surgery. Call your healthcare provider if you have any of the following symptoms:
pain in your upper stomach (abdomen)
fever
yellowing of your skin or eyes (jaundice)
clay-colored stools

depression or thoughts of suicide. You should pay attention to any mental changes, especially sudden changes, in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.
food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Liraglutide injection may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking liraglutide injection before you are scheduled to have surgery or other procedures.
The most common side effects of liraglutide injection in adults include:

nausea
diarrhea
constipation
vomiting
injection site reaction
low blood sugar (hypoglycemia)
headache
upset stomach (dyspepsia)
tiredness (fatigue)
dizziness
stomach pain
change in enzyme (lipase) levels in your blood
Additional common side effects in children are fever and gastroenteritis.
Talk to your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of liraglutide injection. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please read the Medication Guide in the full Prescribing Information, including Boxed Warning.

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

https://finance.yahoo.com/news/final-data-teva-pearl-real-070000414.html

Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki1,2

Fremanezumab demonstrated sustained effectiveness and a favourable safety and tolerability profile over the two-year study period1,2

Injection adherence remained high throughout the study (~90%), while over 75% of patients completed the study duration1

TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevention study showed that AJOVY (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in reducing frequency, duration and severity of migraine attacks in patients with chronic and episodic migraine.1

The final data was presented at the Congress of the European Academy of Neurology (EAN 2025) congress in Helsinki confirming that primary and secondary endpoints had been met.1 Investigators concluded that the findings underscore the sustained effectiveness and the robust injection adherence rates to long-term fremanezumab treatment in migraine prevention.1

“Over the last two years, we have observed the benefit of fremanezumab for sustained migraine prevention and its positive impact on patient outcomes,” says Messoud Ashina, Professor and Director of the Human Migraine Research Unit, the Danish Headache Center and Department of Neurology. “The PEARL study has provided valuable insight, not only
into the pivotal role that fremanezumab can play in migraine prevention, but also in the importance of real-world studies in helping build our knowledge and shape clinical practice.”

PEARL, a 24-month real-world observational study assessed the impact of fremanezumab for migraine prevention in 1,140 patients, predominantly female (87.25%) with 33.1% living with episodic migraine (EM), and 66.9% with chronic migraine (CM). The final study showed

that over 66% of patients with EM and 51.6% with CM who had achieved the primary endpoint of a =50% reduction in Monthly Migraine Days (MMD) during the first 6 months of treatment benefitted from sustained migraine prevention for over 24 months. Injection adherence rates remained high throughout (~90%) the study, with over 75% (854/1129) of participants completing the study duration.1

The investigators also noted the favourable long-term safety and tolerability of fremanezumab that was consistent with its known safety profile from previous PEARL interim analyses and randomised controlled trials, supporting its continued clinical use for migraine prevention.2

“The final analysis of the PEARL real-world study reaffirms the long-term effectiveness and safety profile of fremanezumab in the preventive treatment of chronic and episodic migraine,” said Pinar Kokturk, M.D., Vice President and Head of Medical Affairs Europe at Teva. “These data provide valuable real-world evidence supporting fremanezumab’s sustained clinical benefit, particularly in a population burdened by high disease impact and a need for preventive therapy. With migraine being the second leading cause of disability worldwide,3 the recognition of CGRP-pathway therapies by health authorities is critical for improving patient outcomes.”


Editors’ Notes

PEARL (Pan-European Real-World study), a two-year prospective, observational Phase IV study is investigating the effectiveness of AJOVY® (fremanezumab) in 1140 patients with chronic or episodic migraine. Fremanezumab is a humanised monoclonal antibody (mAb) that selectively targets the calcitonin gene-related peptide (CGRP) pathway. Of the 1140 participants enrolled, 1129 were included in the effectiveness analysis (EM, 33.1%; CM, 66.9%; 87.2% female). Eligible participants were adults with EM or CM receiving fremanezumab for migraine prevention, who maintained a daily headache diary prior to and throughout the study period. The primary endpoint was the proportion of participants with >=50% reduction in monthly migraine days (MMD) during the 6-month period after fremanezumab initiation. Secondary endpoints across Months 1–24 included mean change from baseline in MMD, and treatment adherence (participants who took their prescribed dose within ±5 days of the scheduled monthly/quarterly dosing regimen, per injection) and persistence.


About AJOVY® (fremanezumab-vfrm) injection
AJOVY is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled syringe or, in some countries, in a pre-filled pen. Two dosing options are available: 225 mg once monthly administered as one subcutaneous injection (monthly
dosing), or 675 mg every three months (quarterly dosing), which is administered as three subcutaneous injections. AJOVY can be administered either by a health care professional or at home by a patient or caregiver. No starting dose is required to begin treatment.


Information for Europe about AJOVY can be found here.

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

https://finance.yahoo.com/news/billionaire-stanley-druckenmiller-dumped-entire-070600603.html

>>Another major step forward for Teva has been its vastly improved balance sheet. Under turnaround specialist CEO Kare Schultz, the company sold off non-core assets and reduced its operating expenses by billons per year. This prudent focus on spending has continued under current CEO Richard Francis. After tipping the scales with more than $35 billion in net debt following the Actavis deal, Teva now has less than $15 billion in net debt.

The other critical action undertaken by Francis has been to shift Teva toward novel-drug development. Though it's still a major player in generic drugs, developing brand-name therapies comes with higher margins and faster growth rates. Tardive dyskinesia drug Austedo looks to push for $2 billion in sales this year, which is up from $963 million in full-year sales in 2022. In other words, Teva has found its Copaxone replacement, and has plenty of other novel therapies ramping up sales and/or in the pipeline.

The cherry on top is that Teva Pharmaceutical Industries remains historically cheap despite its stock more than doubling over the trailing-two-year period. Its forward price-to-earnings ratio of 6.5 is well below other major pharmaceutical stocks and not fully indicative of the company's growth potential or ongoing turnaround.>>

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

https://finance.yahoo.com/news/teva-fosun-pharma-enter-strategic-123000589.html

Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target

https://finance.yahoo.com/news/truist-initiates-teva-pharmaceuticals-teva-175009311.html

On Tuesday, May 27, an analyst from Truist Securities initiated coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $25.

Teva Pharma is an Israeli pharmaceutical company best known as one of the world’s largest manufacturers of generic drugs. In addition to generics, the company sells branded medicines and active pharmaceutical ingredients (APIs), offers contract manufacturing services, and operates an out-licensing platform through its affiliated company, Medis.

The Truist analyst believes the company’s strategy of building a portfolio of high-margin branded products while maintaining its core focus on generics is a key strength of its business model. This dual approach is expected to support sustainable and profitable growth in the years ahead.

The company has recently launched a $700 million cost-cutting initiative aimed at enhancing operational efficiency by reducing headcount and external spending. The analyst believes that this program will support margin improvement and help the company achieve its target of a 30% operating margin by 2027.

As a result of Teva’s continued focus on debt and cost reduction, as well as profitable growth, credit rating agencies Moody’s and Fitch upgraded the company’s corporate credit rating on May 15 and 20, respectively.

While we acknowledge the potential of TEVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has 100x upside potential

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Teva outlines acceleration path into a leading biopharma company

Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® (risperidone) and late-stage pipeline with blockbuster potential

Reaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs

TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acceleration phase of its “Pivot to Growth” strategy and to discuss portfolio priorities as it evolves into a global biopharmaceutical leader. The event, led by President and CEO Richard Francis and members of Teva’s executive management team, will outline the company’s strategy, progress and roadmap to deliver sustained shareholder value through 2030 and beyond.

Presentations begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. A live webcast of the event and presentation materials will be available on Teva's Investor Relations website at: https://ir.tevapharm.com/Events-and-Presentations.

Where We Are Today
Teva has completed Phase 1 of the Strategy: Return to Growth, delivering:

9 consecutive quarters of growth – fueled by strong momentum from key innovative growth drivers.

More than $2.3 billion in revenue in 2024 from Teva’s innovative portfolio: AUSTEDO®, AJOVY®, and UZEDY®.

Returning the generics business to growth with +5% in revenues across regions, and top 3 global portfolio with potential for five product launches by 2027.

“The past two years have been about returning to growth and building a solid foundation. Today, Teva is a fundamentally different company – more focused, more innovative, and more robust. I am proud that we have delivered on our commitments,” said Richard Francis, Teva’s President and CEO. “Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio.”

Delivering on Our Growth Engines
Teva’s innovative portfolio continues to drive strong performance and future potential. The company has announced its target to build a >$5 billion innovative medicines franchise by 2030, driven by AUSTEDO, AJOVY, UZEDY, and a robust pipeline of late-stage assets including olanzapine LAI, duvakitug, DARI, and emrusolmin.

AUSTEDO: Expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion by 2030.

AJOVY: A globally established brand with presence across 43 countries and expected launches in 3 additional countries this year.

LAI schizophrenia franchise expected to have $1.5 billion to $2.0 billion in peak sales

UZEDY: Fastest growing LAI with >60% risperidone LAI market share captured.

Olanzapine LAI: Set to expand our LAI franchise - U.S. NDA filing expected in H2 2025.

Stepping Up Innovation
Teva’s late-stage pipeline includes multiple assets with proven mechanisms and blockbuster potential:

duvakitug (anti-TL1A): A potentially best-in-class treatment for inflammatory bowel disease, with potential expansion into additional indications with peak sales potential of up to $2-$5 billion.

DARI: A dual-action rescue inhaler for asthma, that could address a significant unmet need as a first ICS/SABA combination for both adult and pediatric patient populations, with peak sales potential of ~$1 billion.

olanzapine LAI: A differentiated long-acting injectable for schizophrenia, that we expect to build on the success of UZEDY and expand Teva’s LAI franchise.

emrusolmin: A potential first-in-class treatment for Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease that currently has no approved treatments, with peak sales potential of more than $2 billion.

TEV-‘408: Anti-IL-15 antibody granted fast-track designation by the U.S. Food and Drug Administration (FDA) to be evaluated for the treatment of celiac disease, with peak sales potential of more than $1 billion.

Sustaining Our Generics Powerhouse
Teva’s generics, biosimilars, and OTC business remains a stable, robust and cash-generating powerhouse. Teva continues to lead in generics globally, with a strong pipeline of complex generics and biosimilars.

13 biosimilars in the pipeline, with potential for 5 new launches planned by 2027.

Strategic focus on complex generics, biosimilars, and OTC to compensate gRevlimid by 2027.

Expanding on our $1.1 billion OTC business with a global portfolio of strong local and global brands, outperforming the market with double-digit growth.

Continued manufacturing transformation to enhance competitiveness and margins.

Focusing Our Business
Teva is accelerating shareholder value creation with reaffirmed its 2027 financial targets:

Revenue growth driven by innovative launches and stable generics business.

Operating margin expansion to 30% by 2027.

Free cash flow of >$2.7 billion in 2027 and >$3.5 billion by 2030.

Payment of debt down to 2x net leverage.

~$700 million in net savings through modernizing the organization and improving operational efficiencies, enabling reinvestment in R&D and commercial capabilities.

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
Teva Pharmaceutical Industries Ltd

https://finance.yahoo.com/news/moodys-investor-services-upgrades-teva-221200201.html

TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive.

Moody's report cites the Company's strengths which include significant global scale, ongoing growth in the company’s branded franchises, stabilization of the company’s generics business, focus on debt reduction and resolution of various legal liabilities https://ratings.moodys.com/ratings-news/443085.

“This is a testament to the consistent performance of Teva as a result of the company’s Pivot to Growth strategy,” said Eli Kalif, Chief Financial Officer, Teva Pharmaceuticals. “This upgrade is expected to improve both our cost of debt, and our access to an enhanced base of investors.”

Today

TEVA, 10Q due 1/29

still busting new highs everyday LMFA😭

120%+ on my options from yesterday!


$TEVA

The market unfortunately is flooded with these auto immune products for crohns and ulcerative colitis. Buyer beware.

The market reaction thinks different.
Very different.

Unfortunately for TEVA the market is already flooded with crohns disease and auto immune drugs. They dont have a drug yet but even if they do it will be a competitive pricing blood bath on the market already well served.

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

https://finance.yahoo.com/news/teva-sanofi-announce-duvakitug-anti-123000339.html

Here's another biotech that keeps following a pattern of popping and dropping. lol 7.22 to 7.37 today but looking like it wants to go up again and was over 11 less than 6 months ago.

Thank you...It IS a great plan...Looking forward to trying this elsewhere. =)

Eli Lilly ordered to pay $176.5 mln to Teva in U.S. migraine drug patent trial

Blake Brittain

https://finance.yahoo.com/news/eli-lilly-ordered-pay-176-213004418.html

Nov 9 (Reuters) - Eli Lilly & Co must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal court jury decided on Wednesday.

The jury agreed with Teva that Lilly's Emgality violated its rights in the patents, which relate to its own migraine drug Ajovy. Both drugs treat migraines by employing antibodies to inhibit headache-causing peptides.

The jury also found that Lilly infringed the patents willfully and rejected its argument that the patents were invalid.

A spokesperson for Lilly said the company was disappointed by the verdict but is confident that it will "ultimately prevail" in the case, and said the decision does not affect its ability to offer Emgality to patients.

A Teva spokesperson said the company is pleased with the decision and will "continue to vigorously defend its intellectual property rights."

Indianapolis-based Lilly earned over $577 million from Emgality sales worldwide last year, while Israel-based Teva made $313 million from Ajovy, according to company filings with the U.S. Securities and Exchange Commission.

Teva has said that expects its two branded drugs, Ajovy and Huntington's disease drug Austedo, to generate a combined $1.4 billion in revenue this year.

Teva sued Lilly over the patents in 2018. The same day Teva sued, the court dismissed two related Teva lawsuits seeking to block Emgality from coming onto the U.S. market.

Teva also filed a separate, ongoing patent lawsuit against Lilly in Massachusetts over Emgality last year. (Reporting by Blake Brittain in Washington Editing by David Bario and Deepa Babington)

4.25 $$$$Billion wow

Bought some 7's for this week (.36) and saw we popped in the AH to 8.40's. Can't exercise in the AH and wanted to lock in that almost 300% gain by shorting the shares directly in the AH and covering with my 7 calls but I've got no clue if that's how it works. lol Ever do anything like that?

It's not just a good plan ...

It's a great plan!

Once I got the hang of it, that's all I do and I've been doing it for years. I've gained so much confidence in how well it works such that I only use one stock symbol and go all-in using both my Individual and Retirement accounts.

The only caveat (which posed limits on what I could do years ago) was that one should (pronounced must) only trade stocks that have weekly options, which provides more opportunities to tweak the trades as the options come down in price quicker than they would if you were stuck with monthly expiration options. Using weekly options, I've had no trouble creating very high percentage gains at the end of every month and year.

I was born into a farmer family. My father had milk cows, and he also grew feed crops for those cows. That's a very smart way to run a farm because he didn't have to buy any feed crop from other farmers for the purpose of feeding his cows. Some of the grain that he harvested fed his cows, while the excess grain was sold to dairy farmers which didn't have sufficient land to grow all the feed that they needed. Bingo!

Buy all the stock you can afford. Choose one that is alive and well as shown by its pricing (feeding) habits. You know, like TEVA, as it goes up and down in relatively confined and predictable ranges so your stock might be assigned at the end of the first week or it might not in which case you sell Calls again during the next week, and maybe again during the following week. Hey, if you are going to own stock, at least milk it. If it gets assigned away at the end of the week, buy it back on the following Monday or a little later depending on how it's trending. You might get it cheaper than the price it was assigned at. Or buy that other milk cow you've been watching, then sell its Calls.

Smart and sounds like a good plan.
I've only bought calls and sometimes puts. Haven't sold calls or puts as I feel too new to options and don't want to mess up. I think I accidently sold something once and I noticed it immediately and I made sure I bought it right back.
I assume a 'covered call' is selling the call of the shares you own. Example Buy 1,000 shares of TEVA @ 8 you sell the weekly call of 8 (10 contracts) so if the stock goes down you make money on the option and if it goes up against you the shares balance a gain to what you could lose on selling the option.

Works for me ...

My favorite way of making money on stocks is to buy the shares then sell weekly Covered Calls against the stock week after week.

When finally assigned -- wash, rinse, repeat. That's a steady 52 paychecks every year.

This method even compounds: once assigned, there's more cash to buy more shares and sell more CCs.

However, there's one thing I wont do, which is to chase it downward when it appears to be trending that way. I'd rather just sit on cash and wait for a bottoming pattern.

Under 8 bucks again...

Looks like TEVA might have sat down at the dressing table. Looking forward to them beginning to apply some makeup. Do we wait for the lipstick?